GlassScriptPhysician profile
Wilson Dumornay
NPI 1245327246
$8,520.67
in general payments reported to CMS, 2019-2025
25 companies · $586 in 2025
The $586 reported for 2025 was more than what 75% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $209 · 2021: $555 · 2022: $3,936 · 2023: $2,462 · 2024: $367 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Travel and Lodging: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.47 |
| Travel and Lodging | $1,614.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $3,570.87 | 2021-2022 | |
| Stryker Corporation | $2,111.48 | 2019-2025 | Scopis Ent, Xpress Ent Dilation System, Clarifix Cryotherapy Device |
| Intuitive Surgical, INC. | $828.12 | 2019-2023 | Da Vinci Surgical System |
| Acclarent, INC | $263.02 | 2019 | |
| Optinose US, INC. | $245.94 | 2019-2025 | |
| Genzyme Corporation | $220.59 | 2023-2025 | |
| Glaxosmithkline, LLC. | $142.55 | 2023-2025 | Nucala |
| Alk-Abello, INC | $134.30 | 2019-2022 | |
| Olympus America INC. | $131.25 | 2025 | Rhino-Laryngo Videoscope |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.24 | 2025 | Gattex |
| Regeneron Healthcare Solutions, INC. | $110.84 | 2023-2025 | Dupixent |
| Ethicon US, LLC | $97.42 | 2023-2024 | Stratafix, Vistaseal |
| Phadia US INC. | $76.79 | 2021-2024 | Immunocap |
| W. L. Gore & Associates, INC. | $66.67 | 2023 | Gore Enform Preperitoneal Biomaterial |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $64.76 | 2024 | |
| Smith+Nephew, INC. | $52.68 | 2019-2020 | |
| Aerin Medical INC. | $38.03 | 2019-2024 | |
| Medtronic, INC. | $21.91 | 2024 | Sinuva |
| Merz North America, INC. | $19.23 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.76 | 2024 | Dsuvia |
| Intersect Ent, INC. | $17.89 | 2019 | |
| Lilly USA, LLC | $16.73 | 2025 | Zepbound |
| Galderma Laboratories, L.P. | $14.98 | 2022 | |
| Apyx Medical Corporation | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Dumornay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.